Clinical trial
A Two-Stage Phase 1 Dose Escalation Pharmacokinetic Study of Tarceva in Patients…
NCT00294736 · OSI Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00294736 |
|---|---|
| Title | A Two-Stage Phase 1 Dose Escalation Pharmacokinetic Study of Tarceva in Patients With Stage IIIB/IV Non-small Cell Lung Cancer Who Continue to Smoke After Failure of One or Two Prior Chemotherapy Regimens |
| Official title | A Two-Stage Phase 1 Dose Escalation Pharmacokinetic Study of Tarceva® (Erlotinib) in Patients With Stage IIIB/IV Non-small Cell Lung Cancer Who Continue To Smoke After Failure of One or Two Prior Chemotherapy Regimens |
| Lead sponsor | OSI Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | NSCLC |
| Intervention type | Drug |
| Interventions | Tarceva |
| Enrollment | 57 |
| Start date | Nov 1, 2005 |
| Primary completion | Sep 1, 2007 |
| Completion | Sep 1, 2007 |
| First posted | Feb 22, 2006 |
| Last update posted | Aug 8, 2012 |
| Countries | United Kingdom, United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: